Abstract
Thyroid cancer (TC) is known to be the most common endocrine malignancy worldwide, with incidence rising steadily over recent decades. In the year 2022, an estimated 821,000 new cases were reported globally, with markedly higher age-standardized incidence rates (ASIRs) in women and in high-HDI regions such as Eastern Asia and North America. Improved diagnostic imaging, lifestyle-associated risk factors, environmental exposures, and sex-specific susceptibility contribute to this trend. Although increasing incidence raises concerns about overdiagnosis, which is exacerbated by expanded imaging and screening practices, global age-standardized mortality rates remain low at approximately 0.44 per 100,000. TC encompasses a biologically diverse spectrum ranging from indolent well-differentiated tumors (papillary thyroid carcinoma [PTC], follicular thyroid carcinoma [FTC]) to aggressive entities, including poorly differentiated thyroid carcinoma (PDTC), anaplastic thyroid carcinoma (ATC), and medullary thyroid carcinoma (MTC). While differentiated cancers exhibit excellent long-term survival, aggressive variants and high-grade follicular cell–derived malignancies show significantly higher recurrence and mortality rates, driven by molecular alterations such as BRAF, RAS, TERT promoter, and TP53 mutations. Conventional management relies on surgery, radioactive iodine (RAI) therapy, thyroid stimulating hormone (TSH) suppression, and targeted tyrosine kinase inhibitors (TKIs) for advanced or RAI-refractory disease. Despite therapeutic advances, major gaps persist, including loss of differentiation leading to RAI refractoriness, lack of validated predictive biomarkers, limited efficacy of immune checkpoint inhibitors, incomplete understanding of TKI resistance, and inadequate preclinical models. Emerging multi-omics profiling, spatial immune mapping, and biomarker-driven clinical trial designs are expected to refine risk stratification and enable more personalized therapy for aggressive TCs.